СКРИНИНГ И МОНИТОРИНГ ТУБЕРКУЛЕЗНОЙ ИНФЕКЦИИ У РЕВМАТОЛОГИЧЕСКИХ БОЛЬНЫХ ПРИ ЛЕЧЕНИИ ИНГИБИТОРАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ-a
Методы, оценивающие продукцию ИФН-у, используют гораздо более специфичные для М. tuberculosis антигены, но для их реализации технически гораздо более сложна. В России для решения аналогичных задач разработана кожная проба с оригинальным препаратом ДИАСКИНТЕСТ®-, представляющем собой комплекс белков ESAT-6 и CFP-10. Однако до настоящего времени не решены многие вопросы практического применения… Читать ещё >
Содержание
- Список сокращений
Глава 1. Обзор литературы. Ревматологические пациенты, получающие ингибиторы фактора некроза опухоли — группа повышенного риска развития туберкулеза.
1.1. Роль фактор некроза опухоли в норме и при патологии.
1.2. Ингибиторы фактор некроза опухоли в ревматологической практике.
1.3. Риск туберкулеза у больных с ревматологическими заболеваниями и возможности его снижения.
1.4. Исследование специфического противотуберкулезного иммунитета — методы оценки вероятности наличия латентной туберкулезной инфекции.
Глава 2. Методы исследования и общая характеристика клинических наблюдений.
2.1. Общая характеристика дизайна и объема исследования.
2.2. Методы исследования.
2.3. Статистическая обработка результатов исследования.
2.4. Общая характеристика включенных в исследование больных.
Глава 3. Обследование больных ревматологическими заболеваниями на туберкулез перед лечением ингибиторами ФНО-а
3.1 Задачи обследования на туберкулез перед лечением ингибиторами ФНО-а и характеристика обследованных больных.
3.2. Выявление активного туберкулеза.
3.3. Признаки перенесенного туберкулеза и оценка активности остаточных изменений.
3.4. Определение риска латентной туберкулезной инфекции.
3.4.1. Результаты пробы Манту с 2 ТЕ.
3.4.2. Результаты кожной пробы с аллергеном туберкулезным рекомбинантным.
3.4.3. Результаты пробы на продукцию ИФН-у in vitro.
3.4.4. Сопоставление результатов иммунологических проб.
Глава 4. Обследование больных ревматологическими заболеваниями на туберкулез в процессе лечения ингибиторами ФНО-а
4.1 Задачи обследования на туберкулез в процессе лечения ингибиторами ФНО-а и характеристика обследованных больных.
4.2 Исключение заболевания туберкулезом или реактивации посттуберкулезных изменений.
4.3. Мониторинг латентной туберкулезной инфекции.
4.3.1. Результаты пробы Манту с 2 ТЕ.
4.3.2. Результаты кожной пробы с аллергеном туберкулезным рекомбинантным.
4.3.3. Результаты пробы на продукцию ИФН-у in vitro.
4.3.4. Сопоставление результатов иммунологических проб.
4.3.5. Пробы со специфическими антигенами МБТ при изменениях результатов пробы Манту с 2 ТЕ в ходе лечения ингибиторами ФНО-а.^^
ГЛАВА 5. Особенности туберкулеза у больных на фоне лечения ингибиторами ФНО- а.
Список литературы
- Постановление Правительства Российской Федерации от 25 декабря 2001 г. № 892 «О реализации Федерального закона „О предупреждении распространения туберкулеза в Российской Федерации“».
- Приказ Министерства здравоохранения Российской Федерации от 21 марта 2003 года № 109 «О совершенствовании противотуберкулезных мероприятий в Российской Федерации».- М., 2003. 347 с.
- Авербах М.М., Гергерт В. Я., Литвинов В. И. Повышенная чувствительность замедленного типа и инфекционный процесс // М.: Медицина.-1974. 246 С.
- Александрова E.H., Морозова Т. И., Паролина Л. Е., Докторова Н. П. Интерпретация комплексной когортной оценки результатов туберкулино-диагностики // Пробл. туб. и болезней легких. 2008. — № 7. — С. 23−26.
- Воловатова И.Н., Кузнецов А. Н. Изменения легочной вентиляции у больных ревматоидным артритом // Мед. альманах.- 2009.- № 1.- С. 212−215.
- Гланц С. Медико-биологическая статистика. Пер. с англ.- М.- Практика, 1998, — 459 с.
- Дзяк Г. В. Поражение органов дыхания в ревматологической практике // Укр. пульмон. журн. 2000. — № 1.- С. 5−11.
- Киселёв В.И., Барановский П. М., Пупышев С. А. и др. Новый кожный тест для диагностики туберкулёза на основе рекомбинантного белка ESAT-CEF// Молекулярная медицина.-2008.-№ 4.-С.28−34.
- Кодолова И.М., Преображенская Т. М. Изменение лёгких при системных заболеваниях соединительной ткани.- М.-Медицина.- 1980.- 144 с.
- П.Лебедева Л. В., Грачева С. Г. Чувствительность к туберкулину и инфицированность микобактериями туберкулеза у детей // Проб л. туб. и болезней легких. М. — 2007, с. 5−9
- Литвинов В.И. Латентная туберкулезная инфекция миф или реальность? // Туберкулез и болезни легких.- 2011.- № 6.- С. 3−9.
- Лукина Г. В., Сигидин Я. А., Насонов Е. Л. Применение инфликсимаба у больных ревматоидным артритом в клинической практике (по данным Российского регистра) // Тер. Архив.- 2009.- № 8.- С. 1−5.
- Мазуров В.И., Богданов А. Н. Диагностика и лечение поражений лёгких у больных ревматоидным артритом // Научно-практич. ревматология.- 2003,-№ i.-c. 52−56.
- Насонов Е.Л., Козлов P.C., Якушин С. Б. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден — значит вооружен // Клин, микробиол. антимикроб, химиотер.- 2006, — Т. 8.-№ 4.- С. 38−48.
- Палеев Н.Р., Царькова JI.H. Лёгочные синдромы при ревматических болезнях / Болезни органов дыхания.- М.- Медицина.- 1990.-Т. 4.- С. 396−424.
- Паролина Л.Е., Завалев В. И., Морозова Т. И. Туберкулез легких: социальные проблемы. Саратов.: Изд-во Сарат. мед. ун-та. — 2003. — 151 с.
- Петри А., Сэбин К. Наглядная медицинская статистика. Пер. с англ.- 2-е изд.- М.: ГЭОТАР-Медиа, 2010.- 168 с.
- Рунион Р. Справочник по непараметрической статистике. Современный подход. Пер. с англ.- М.- Финансы и статистика, 1982.- 198 с.
- Сергиенко В.И., Бондарева И. Б. Математическая статистика в клинических исследованиях.- М.- ГЭОТАР-МЕД, 2001.- 256 с.
- Слогоцкая Л.В., Филиппов A.B., Кочетков Я. А. и др. Чувствительность и специфичность Диаскинтеста у больных туберкулезом и нетуберкулезными заболеваниями лёгких // Российский мед. журнал. 2011. — № 4. -С. 15−19.
- Тюлькова Т.Е., Корначев A.C., Чугаев Ю. П. и др. Прогностическиекритерии перехода латентного туберкулеза в клинически активный // Проблемы туберкулеза и болезней легких. 2008. — № 7. — с. 29−35.
- Фтизиатрия: национальное руководство / под ред. М.И. Перель-мана.- М.: ГЭОТАР- Медиа, 2007.- 512 с.
- Шилова М.В. Туберкулез в России в 2008 году//М.-2009.-143с.
- Эйнис B.JI. Туберкулез. Клиника, профилактика и лечение// М.: Медгиз.- 1961.-с. 88−92.
- Adams L., Mason С., Kolls J. et al. Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus // J. Infect. Dis.- 1995.- Vol. 171.- P. 400−405.
- Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009- 48: 954−962.
- Agusti C., Xaubet A., Roca J. et al. Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up // Thorax.- 1992. -Vol. 47.-P. 1035−1040.
- Andersen P., Doherty Т., Pai M., Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? // Trends Mol Med. 2007. — v. 13(5). — p. 175 182.
- Andersen P., Munk M., Pollock J., Doherty T. Specific immune-based diagnosis of tuberculosis // Lancet. 2000. — Vol. 356. — P. 1099−1104.
- Anon. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000- 161: S221-S247.
- Arend S., van Meijgaarden K., de Boer K. et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M kansasii И J Infect Dis. 2002. -Vol.186.-P.1797−1807.
- Armbrust W, Kamphuis SS, Wolfs TW, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2004- 43: 527−529.
- Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005- 52: 1986−1992.
- Bakir M., Millington K., Soysal A. et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact // Ann Intern Med. 2008. — Vol. 149(11). — P. 777−787.
- Barry C., Boshoff H., Dartois V. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev Microbiol 2009- 7: 845−855.
- Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009- 33: 586−593.
- Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001- 11: 372−377.
- Baum J. Infection in rheumatoid arthritis // Arthr. Rheum.- 1971.-Vol. 14.-P. 135−137.
- Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007- 137: 620−622.
- Behar SM, Shin DS, Maier A, et al. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol 2009- 36: 546−551.
- Behr M., Wilson M., Gill W. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray // Science. 1999. — V. 284. — P. 1520−1523.
- Bekker LG, Freeman S, Murray PJ, et al. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001- 166: 6728−6734.
- Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005- 9: 1057−1058.
- Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003- 171: 3110−3118.
- Boussiotis V., Tsai E., Yunis E. et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients // J Clin Invest. 2000. — Vol. 105(9).-P. 1317−1325.
- Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006- 43: 717−722.
- Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009- 61: 300−304.
- British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005- 60: 800−805.
- Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009- 119:1167−1177.
- Carmona L., Gomez-Reino J., Rodriguez-Valverde V. et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005- 52: 1766−1772.
- Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003- 30: 14 361 439.
- Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factoralpha: California, 2002−2003. MMWR Morb Mortal Wkly Rep 2004- 53: 683−686.
- Cervantes-Perez L., Toro-Perez L., Rodriguez-Jurado M. Pulmonary involment in rheumatoid arthritis. //JAMA.- 1980.- Vol.- 243.- P. 1715−1719.
- Cobanoglu N, Ozcelik U, Kalyoncu U, et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumor necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007- 11:1177−1182.
- Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010- 362: 1383−1395.
- Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007- 132: 52−65.
- Covert B., Spencer J., Orme I., Belisle J. The application of proteomics in defining the T-cell antigens of Mycobacterium tuberculosis II Proteomics. 2001.-Vol. l.-P. 574−586.
- David J., Edmonds S. Rheumatoid arthritis and the lung / Pulmonary involvements in systemic autoimmune diseases. Ed. By Wells A., Denton Ch.
- Chapter 8.- Elsevier, 2004.- P. 147−160.th
- Dawson B., Trapp R. Basic and clinical biostatistics.- 4 ed.- Lange
- Medical Books / McGraw-Hill, 2004.- 438 p.
- Dekker L, Armbrust W, Rademaker CM, et al. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2004- 22: 252−258.
- Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007- 45: 322−328.
- Diel R., Loddenkemper R., Meywald-Walter K. et al. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot. TB test in contact investigations for tuberculosis // Chest. 2009. — Vol. 135(4).-P. 1010−1018.
- Dillon D., Alderson M., Day H. et al. Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. // J. Clin. Microbiol. 2000. -Vol. 38. — P.3285−3290.
- Doherty T., Demissie A., Olobo J. et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients // J Clin Microbiol. 2002. — Vol. 40(2). -P. 704−706.
- Dosanjh D., Hinks T., Innes J., et al. Improved diagnostic evaluation of suspected tuberculosis // Ann Intern Med. 2008. — Vol. 148. — P. 325−336.
- Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005- 41: Suppl. 3, S199-S203.
- Ewer K., Deeks J., Alvarez L. et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak // Lancet. 2003. — Vol. 361. — P. 1168−1173.
- Favalli E., Desiati F., Atzeni F. et al. Serious infections during anti-TNFa treatment in rheumatoid arthritis patients // Autoimmun. Rev. 2009. — Vol. 8. — P. 266−273.
- Feldmann M, Brennan FM, Williams RO, et al. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Prac Res Clin Rheumatol 2004- 18: 5980.
- Flynn J., Chan J. Immunology of tuberculosis // Annu Rev Immunol. -2001.-Vol. 19.-P. 93−129.
- Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factoralpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995- 2: 561−572.
- Fonseca JE, Canhao H, Silva C, et al. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience. Acta Reumatol Port 2006- 31: 247−253.
- Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximabtreated patients with disseminated tuberculosis. Clin Infect Dis 2005- 40: 756−759.
- G.E.A.R. Rheumatoid Arthritis study group. Portuguese society for rheumatology. Tuberculosis in patients treated with anti-TNF-alpha therapy. The Portuguese experience // Ann. Rheum. Dis.- 2006.- Vol. 65.- Suppl. II, 498.
- Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008- 67:1145−1152.
- Gey van Pittius NC, Sampson SL, Lee H, et al. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol Biol 2006- 6: 95.
- Goletti D, Stefania C, Butera O, et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study // PLoS ONE 2008−3:e3417)
- Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007- 57: 756−761.
- Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and openlabel extension study. J Am Acad Dermatol 2006- 55: 598−606.
- Greveson K. Can ELISpot replace the tuberculin skin test for latent tuberculosis? // Br J Nurs. 2009. — Vol. 18(20). — P. 1248−1254.
- Guinn K., Hickey M., Mathur S. et al. Individual RDl-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis // Mol. Microbiol. 2004. — v. 51. — p. 359−370.
- Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002- 359: 1541−1549.
- Harboe M., Oettinger T., Wiker H. et al. Evidence for occurrence of the ESAT-6 protein in M. tuberculosis and virulent M. bovis and for its absence in M. bovis BCG. // Infect. Immun. 1996. — Vol. 64. — P. 16−22.
- Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005- 115: 1−20.
- Hoyles R.K., Wells A.U. Pulmonary fibrosis in collagen vascular disease, Diffuse Parenchymal Lung Diseases. Ed. by Costabel U., du Bois R.M., Egan J.J.- Progr. Respir. Res., Basel, Karger, 2007,.- Vol. 36.- P. 185−195.
- Hsu K. Tuberculin reaction in children treated with isoniazid //Am J Dis Child. 1983. — Vol. 137(11). — P. 1090−1092.
- Huebner R., Schein M., Bass J. The tuberculin skin test // Clin Infect Dis. 1993. — Vol. 17(6). — P. 968−975.
- Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis 2009- 15: 816−822.
- Jakubowiak W., Bogorodskaya E., Borisov S. et al. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions // Int. J. Tuberc. Lung Dis.- 2007. Vol. 11.- N. 1, — 46−53
- Jafari C., Lange C. Suttons’s Law: local immunodiagnosis of tuberculosis // Infection. 2008. — Vol. 36. — P. 510 — 514.
- Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000. Thorax 2000- 55: 887−901.
- Joven B., Almodovar R., Galindo M. Does anti-tumour necrosis factor a treatment modify the tuberculin PPD response? // Ann.Rheum.Dis.- 2006.-Vol. 65.- P. 699.
- Kampmann B, Whittaker E, Williams A, et al. Interferon-1 release assays do not identify more children with active tuberculosis than the tuberculin skin test // Eur Respir J. 2009. — Vol. 33. — P. 1371−1379.
- Kaufmann SHE, Cole ST, Mizrahi V, et al. Mycobacterium tuberculosis and the host response. J Exp Med 2005- 201: 1693−1697.
- Kavanagh PM, Gilmartin JJ, O’Donnell J, et al. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir Med J 2008- 101: 6−7.
- Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New Engl J Med 2001- 345: 1098−1104.
- Kindler V., Sappino A., Grau G. et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection // Cell. 1989. — Vol. 56(5). — P. 731 -740.
- Laffitte E., Janssens J., Roux-Lombard P. et al. Tuberculosis
- Screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test // Br J Dermatol. 2009. — Vol. 161(4). — P. 797−800.
- Lalvani A, Millington KA. T cell-based diagnosis of childhood tuberculosis infection. Curr Opin Infect Dis 2007- 20: 264−271.
- Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001- 357: 2017−2021.
- Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003- 349: 2014−2022.
- Lin PL, Plessner HL, Voitenok NN, et al. Tumor necrosis factor and tuberculosis. J Investig Dermatol Sym Proc 2007- 12: 22−25.
- Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008- 58: 1496−1504.
- Mack U., Migliori G., Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to Mycobacterium tuberculosis'? A TBNET consensus statement // Eur Respir J. 2009. — Vol. 33. — P. 956−973.
- Mahairas G., Sabo P., Hickey M. et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis II J. Bacteriol. 1996. -Vol. 178. — P. 1274−1282.
- Mariette X., Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003- 62: 791.
- Martin J., Walsh C., Gibbs A. et al. Comparison of interferon-crelease assays and conventional screening tests before tumour necrosis factor-a blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010- 69: 181−185.
- Mazurek G., Jereb J., Lobue P. et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States // MMWR Recomm Rep. 2005. — Vol. 54. — P. 49−55.
- McKinney J., Honer zu Bentrup K., Munoz-Elias E. et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the gly-oxylate shunt enzyme isocitrate lyase. // Nature. 2000. — v. 406. — p. 735−738.
- McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007- 11: 1−158, iii-iv.
- Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008- 58: 106−115.
- Menzies D., Pai M., Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research // Ann Intern Med. 2007. — Vol. 146. — P. 340−354.
- Menzies R. Tuberculin skin testing. In: Reichman LB, Hershfield ES, editors. Tuberculosis: a comprehensive international approach. New York: Marcel Dekker. Inc., 2000. — P. 279−322.
- Mines D, Novelli L. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2007- 44: 619−620.
- Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001- 69: 1847−1855.
- Moreira AL, Tsenova L, Aman MH, et al. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosisinfected mice. Infect Immun 2002- 70: 2100−2107.
- Mori T. Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. J Infect Chemother 2009- 15: 143 155.
- Murakami S, Takeno M, Kirino Y, et al. Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis. Tuberculosis (Edinb) 2009- 89: 136−141.
- Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med 2002- 346: 623−626.
- Nemeth J, Winkler H., Zwick R., et al. Recruitment of Mycobacterium tuberculosis specific CD4+T cells to the site of infection for diagnosis of active tuberculosis. // J Intern Med. 2009. — v. 265. -p. 163−168.
- Newton SM, Brent AJ, Anderson S, et al. Paediatric tuberculosis. Lancet Infect Dis 2008- 8: 498−510.
- Orme M. The latent tuberculosis bacillus (I'll let you know if I ever meet one) // Int J Tuberc Lung Dis.-2001. Vol. 5(7). — P. 589−593.
- Pai M, Menzies D. The new IGRA and the old TST: making good use of disagreement. Am J Respir Crit Care Med 2007- 175: 529−531.
- Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008- 149: 177−184.
- Pai M. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review // The Lancet infectious diseases. 2004. — Vol. 4(12).-P. 761−776.
- Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008- 358: 241−251.
- Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005- 64: 1360−1361.
- Pulmonary involvements in systemic autoimmune diseases Ed. By Wells A., Denton Ch. Elsevier, 2004.-294 p.
- Raval A, Akhavan-Toyserkani G, Brinker A, et al. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007- 147: 699−702.
- Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005- 366: 1367−1374.
- Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008- 58: 224−231.
- Rieder HL. Epidemiologic basis of tuberculosis control. Paris, International Union Against Tuberculosis and Lung Disease, 1999.
- Ruperto N., Lovell D., Cuttica R. et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007- 56: 3096−3106.
- Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009- 36: 1078−1082.
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005- 353: 24 622 476.
- Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008- 59: 762−784.
- Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007- 357: 228−238.
- Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007- 357: 239−250.
- Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007- 34: 706−711.
- Sester U, Junker H, Hodapp T, et al. Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 2006- 21: 3258−3268.
- Shi L., North R., Gennaro M. Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung // Infect Immun. 2004. — Vol. 72(4). — P. 2420−2424.
- Solovic I., Sester M., Gomez-Reino J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement IIEur Respir J 2010- VOLUME 36 NUMBER 5 p. 1185−1206
- Stead W. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy // Ann Intern Med. 1995. — Vol. 122(12). — P. 906−912.
- Styblo K. The relationship between the risk of tuberculosis infection and the risk of developing infectious tuberculosis // Bull Int Union Tuberc. 1985. -Vol. 60.-P. 117−119.
- Sutherland I. The evolution of clinical tuberclosis in adolescents // Tubercle. 1966. — Vol. 47. — P. 38.
- Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997- 337: 1029−1035.
- Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 2007- 67: 1703−1723.
- Villiger PM, Zellweger JP, Moller B. Novel screening tools for latent tuberculosis: time to leave an old friend? Curr Opin Rheumatol 2009- 21: 238−243.
- Vynnycky E., Fine P. Lifetime risks, incubation period, and serial interval of tuberculosis // Am J Epidemiol. 2000. — Vol. 152(3). — P. 247−263.
- Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003- 10: 45−65.
- Wallis RS, Broder M, Wong J, et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004- 39: 1254−1255.
- Wallis RS. Tumor necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008- 8: 601−611.
- Westermann J., Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body // Clin Investig. 1992. — Vol. 70. — P. 539 544.
- Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004- 50: 372−379.
- Woolacott NF, Khadjesari ZC, Bruce IN, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 2006- 24: 587−593.
- Yamada T., Nakajima A., Inoue E., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan // Ann Rheum Dis 2006- 65 № 12.-: 1661−1663.